Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.


Project Scope

The scope of this project is to evaluate and recommend approaches for SEND harmonization to better enable analysis of historical control data. SEND harmonization strategies include creation of new variables, controlled terminology, preferred terms, reference lists and/or analysis strategies (scripts) to enable cross-study analysis. Developing a solution framework for variability that includes representation of stakeholders involved in the creation and use of SEND datasets will enable more efficient routine analysis of warehoused SEND data.



()Katie Warren ()

Project Leads

Email

Kevin Synder (Snyder, FDA)

kevin.snyder@fda.hhs.gov

Mark Carfagna

, Eli Lilly

carfagna_mark_a@lilly.com

Alex Pearce, PHUSE Project Assistantkatie@phuse

Alexandra@phuse.global

Objectives & DeliverablesTimelinesPHUSE Publication of White Paper: Recommendations for Consistent Representation of Test Facilities, Test Sites, and Subject Metadata Using SEND Controlled TerminologyQ2 2022


Status
colourBlue
titleCurrent Status
Q1 2023 Q4 2023

  • Re-scoping the project to focus on virtual control data




Objectives & DeliverablesTimelines
Develop plans for a new, re-scoped project that will focus exclusively on applying harmonisation of SEND data to facilitate implementation of virtual control groups in toxicology studies
.
Resources 
Recommendations for Populating Control Type (TCNTRL) with CDISC SEND Controlled Terminology

Project Members 

Organisation Annika KreuchwigBayerBill HouserBristol Myers Squibb,  BioCelerate ConsortiumCara Rinaldi BioCelerate

Cheryl Sloan

Bristol Myers Squibb,  BioCelerate Consortium

Deepa Smant

ComcastFrank BringezuMerck 

Gen Sato

Eisai Joseph Horvath Bristol Myers SquibbLaura Kaufman PointcrossLokesh Babu PointcrossMichael DeNieu LabcorpMichael WaskoPDS Life Sciences 

Michele Dunleavy

BiocelerateNicolas PhilippePointCross Life Sciences Patricia BrundageFDARick ThompsonJanssen Research & Development,  BioCelerate Consortium

Rupesk Katta

XybionSivaRamaKrishna VemiReddy PointcrossSteve PolleyGSK

Sudharrshan Muthukumarasamy

XybionSue DehavenSanofiTodd PageEli LillyVidhuna SadanandanLabcorpWang WenxianBristol Myers Squibb,  BioCelerate Consortium
Q2 2023
Continued work on consulting with other consortia to understand the critical data needed for virtual controls definingQ3 2023
Host a workshop at the PHUSE CSSQ3 2023
William Houser Bristol Myers Squibb